

Data Sharing Statement

Schram. Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors. *JAMA Oncol*. Published November 17, 2022. doi:10.1001/jamaoncol.2022.5218

Data

Data available: Yes

Data types: Deidentified participant data

How to access data: Upon request, and subject to review, Pfizer will provide the data that support the findings of this study. Subject to certain criteria, conditions and exceptions, Pfizer may also provide access to the related individual de-identified participant data. See <https://www.pfizer.com/science/clinical-trials/trial-data-and-results> for more information.

When available: With publication

Supporting Documents

Document types: Other (please specify)

Additional Information: Supplementary Data

How to access documents: The supplementary data should be published along with the manuscript

When available: With publication

Additional Information

Who can access the data: Anyone requesting the data

Types of analyses: For any purpose

Mechanisms of data availability: With investigator support